Trending NewsTrending NewsNASDAQ:ROIV Roivant Sciences (ROIV) Stock Price, News & Analysis $37.45 +0.65 (+1.77%) Closing price 10/22/2026 04:00 PM EasternExtended Trading$37.95 +0.50 (+1.34%) As of 10/22/2026 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Roivant Sciences Stock (NASDAQ:ROIV) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Roivant Sciences alerts:Sign Up Key Stats Today's Range$36.68▼$38.4950-Day Range$33.35▼$41.8152-Week Range$17.89▼$42.50Volume13.45 million shsAverage Volume6.01 million shsMarket Capitalization$27.05 billionP/E RatioN/ADividend YieldN/APrice Target$45.64Consensus RatingModerate Buy Company Overview Roivant Sciences Ltd. (NASDAQ: ROIV) is a biopharmaceutical company focused on discovering, developing and commercializing medicines. The company organizes its activities through subsidiaries and partner companies, often referred to as “Vants,” which specialize in particular therapeutic areas and stages of drug development. Roivant’s research and development activities have included immunology, dermatology, women’s health, rare diseases and other specialty-care fields. Its portfolio has included Vtama (tapinarof) cream, a nonsteroidal topical treatment approved in the United States for plaque psoriasis and atopic dermatitis. The company also supports clinical-stage programs and partnerships designed to advance potential treatments for immune-mediated and other serious diseases. Founded in 2014 by Vivek Ramaswamy, Roivant is headquartered in Basel, Switzerland, and maintains operations and commercial activities in the United States and other international markets. Matt Gline has served as the company’s chief executive officer since 2021. Roivant uses a combination of internal research, acquisitions, licensing arrangements and strategic partnerships to build and advance its biopharmaceutical portfolio.AI Generated. May Contain Errors. Read More Roivant Sciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks51st Percentile Overall ScoreROIV MarketRank™: 2.535623917965 of 5 starsRoivant Sciences scored higher than 51% of companies evaluated by MarketBeat, and ranked 455th out of 903 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.1 / 5Analyst RatingModerate Buy Consensus RatingRoivant Sciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.79, and is based on 1 strong buy rating, 10 buy ratings, 2 hold ratings, and 1 sell rating.Upside PotentialRoivant Sciences has a consensus price target of $45.64, representing about 21.9% upside from its current price of $37.45.Amount of Analyst CoverageRoivant Sciences has been the subject of 11 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Roivant Sciences' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Roivant Sciences are expected to decrease in the coming year, from ($2.00) to ($2.23) per share.Price to Book Value per Share RatioRoivant Sciences has a P/B Ratio of 5.10. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Roivant Sciences' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted5.97% of the float of Roivant Sciences has been sold short.Short Interest Ratio / Days to CoverRoivant Sciences has a short interest ratio ("days to cover") of 4.43.Change versus previous monthShort interest in Roivant Sciences has recently increased by 8.61%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldRoivant Sciences does not currently pay a dividend.Dividend GrowthRoivant Sciences does not have a long track record of dividend growth. News and Social Media2.8 / 5News Sentiment0.47 News SentimentRoivant Sciences has a news sentiment score of 0.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 20 news articles for Roivant Sciences this week, compared to 5 articles on an average week.Search InterestOnly 3 people have searched for ROIV on MarketBeat in the last 30 days. This is a decrease of -63% compared to the previous 30 days.MarketBeat Follows6 people have added Roivant Sciences to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Roivant Sciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $65,848,636.00 in company stock.Percentage Held by Insiders8.80% of the stock of Roivant Sciences is held by insiders.Percentage Held by Institutions64.76% of the stock of Roivant Sciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Roivant Sciences' insider trading history. Receive ROIV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Roivant Sciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ROIV Stock News HeadlinesRoivant Sciences Ltd. announces positive results in CLARITY-1 and CLARITY-2 phase 3 trials for brepocitinibOctober 22 at 1:28 AM | msn.comStocks making the biggest moves midday: SpaceX, Meta Platforms, Super Micro Computer, Roivant Sciences & moreOctober 21 at 8:28 PM | cnbc.comThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Because my research has led me to believe we’re risking World War 3 with Iran for a completely different reason. | Banyan Hill Publishing (Ad)Roivant Sciences Ltd. (ROIV) Discusses Phase 3 Results for Brepocitinib in Non-Infectious Uveitis TranscriptOctober 21 at 4:00 PM | seekingalpha.comRoivant Sciences Says Brepocitinib Meets Primary Goal In Uveitis Trials; Shares RiseOctober 21 at 10:27 AM | rttnews.comRoivant Sciences stock surges on positive uveitis trial dataOctober 21 at 10:27 AM | finance.yahoo.comRoivant Sciences (NASDAQ:ROIV) Director Sells 17,750 Shares of Company StockOctober 6, 2026 | insidertrades.comRoivant Sciences (NASDAQ:ROIV) CEO Eric Venker Sells 200,000 Shares of StockOctober 3, 2026 | insidertrades.comSee More Headlines ROIV Stock Analysis - Frequently Asked Questions How have ROIV shares performed this year? Roivant Sciences' stock was trading at $21.70 at the beginning of the year. Since then, ROIV shares have increased by 72.6% and is now trading at $37.45. How were Roivant Sciences' earnings last quarter? Roivant Sciences Ltd. (NASDAQ:ROIV) released its earnings results on Friday, August, 7th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.30) by $0.04. The business earned $1.44 million during the quarter, compared to analyst estimates of $2.06 million. Roivant Sciences had a negative net margin of 3,534.96% and a negative trailing twelve-month return on equity of 22.94%. Read the conference call transcript. Who are Roivant Sciences' major shareholders? Roivant Sciences' top institutional shareholders include Assenagon Asset Management S.A. (1.02%), Yousif Capital Management LLC (0.02%), Sumitomo Mitsui DS Asset Management Company Ltd (0.01%) and State of Alaska Department of Revenue (0.01%). Insiders that own company stock include Sciences Ltd Roivant, Vivek Ramaswamy, Financial Lp Qvt, Mayukh Sukhatme, Matthew Gline, Frank Torti, Daniel Allen Gold, Keith S Manchester, Eric Venker, Richard Pulik, Rakhi Kumar, Jennifer Humes and Melissa B Epperly. View institutional ownership trends. How do I buy shares of Roivant Sciences? Shares of ROIV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Roivant Sciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Roivant Sciences investors own include NVIDIA (NVDA), Palantir Technologies (PLTR), Tesla (TSLA), Advanced Micro Devices (AMD), Broadcom (AVGO), Energy Transfer (ET) and UiPath (PATH). Company Calendar Last Earnings8/07/2026Today10/22/2026Next Earnings (Estimated)11/09/2026Jefferies Global Healthcare Conference11/17/2026CMD 202612/09/2026Fiscal Year End3/31/2027Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (2d) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 As of 2 days ago, ROIV's financial health entered the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:ROIV CIK1635088 Webroivant.com Phone44-20-7400-3347FaxN/AEmployees721Year Founded2014Price Target and Rating Average Price Target for Roivant Sciences$45.64 High Price Target$55.00 Low Price Target$33.00 Potential Upside/Downside+21.9%Consensus RatingModerate Buy Rating Score (0-4)2.79 Research Coverage14 Analysts Profitability EPS (Trailing Twelve Months)($0.53) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$299.77 million Net Margins-3,534.96% Pretax Margin-3,848.65% Return on Equity-22.94% Return on Assets-21.53% Debt Debt-to-Equity RatioN/A Current Ratio16.72 Quick Ratio16.72 Sales & Book Value Annual Sales$8.26 million Price / Sales3,274.93 Cash FlowN/A Price / Cash FlowN/A Book Value$7.35 per share Price / Book5.10Miscellaneous Outstanding Shares722,320,000Free Float658,759,000Market Cap$27.05 billion OptionableOptionable Beta1.10 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:ROIV) was last updated on 10/22/2026 by MarketBeat.com Staff. From Our PartnersTicker Revealed: Pre-IPO Access to "Next Elon Musk" CompanyWe’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billi...Banyan Hill Publishing | SponsoredALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Roivant Sciences Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Roivant Sciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
